Literature DB >> 22916313

A Case of Palmoplantar Pustulosis Induced by Certolizumab Pegol: New Anti-TNF-alpha Demonstrates the Same Class Effect.

Michael L Shelling1, Magalys Vitiello, Emma L Lanuti, Maria Miteva, Paolo Romanelli, Francisco A Kerdel.   

Abstract

The development of de novo psoriasis in patients treated with tumor necrosis factor-alpha antagonists is well recognized. The authors hereby report a case of palmplantar pustular psoriasis in a patient with rheumatoid arthritis treated with etanercept. The condition responded to topical steroids but re-occurred upon treating the patient with certolizumab pegol. This strongly suggests that the development of de novo psoriasis is a class effect.

Entities:  

Year:  2012        PMID： 22916313      PMCID： PMC3424592     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


  6 in total

1.  Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.

Authors:  Jean David Cohen; Irina Bournerias; Valérie Buffard; Agnès Paufler; Xavier Chevalier; Martine Bagot; Pascal Claudepierre
Journal:  J Rheumatol       Date:  2006-10-01       Impact factor: 4.666

Review 2.  Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Authors:  Angelique N Collamer; Daniel F Battafarano
Journal:  Semin Arthritis Rheum       Date:  2010-06-26       Impact factor: 5.532

Review 3.  Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review.

Authors:  Aikaterini-Evaggelia Moustou; Athina Matekovits; Clio Dessinioti; Christina Antoniou; Petros P Sfikakis; Alexander J Stratigos
Journal:  J Am Acad Dermatol       Date:  2009-07-22       Impact factor: 11.527

Review 4.  Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Authors:  Uwe Wollina; Gesina Hansel; André Koch; Jaqueline Schönlebe; Erich Köstler; Gunter Haroske
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

5.  Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.

Authors:  R Fleischmann; J Vencovsky; R F van Vollenhoven; D Borenstein; J Box; G Coteur; N Goel; H-P Brezinschek; A Innes; V Strand
Journal:  Ann Rheum Dis       Date:  2008-11-17       Impact factor: 19.103

6.  Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  M J Harrison; W G Dixon; K D Watson; Y King; R Groves; K L Hyrich; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2008-04-02       Impact factor: 19.103
  6 in total
  2 in total

1.  Paradoxes in dermatology.

Authors:  Keshavmurthy A Adya; Arun C Inamadar; Aparna Palit
Journal:  Indian Dermatol Online J       Date:  2013-04

2.  Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review.

Authors:  Anna Gawdzik; Małgorzata Ponikowska; Alina Jankowska-Konsur; Zdzisław Woźniak; Joanna Maj; Jacek C Szepietowski
Journal:  Dermatol Ther (Heidelb)       Date:  2020-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.